| Type | Title | Date Released | |
|---|---|---|---|
6-K | Vicore Pharma Announces Third Quarter 2026 Financial Results and Business Update | ||
6-K | Vicore Announces Nomination Committee for the 2027 Annual General Meeting | ||
6-K | Vicore’s Phase 2b ASPIRE Trial of Buloxibutid in IPF Passes Pre-Planned Futility Analysis and Remains on Track for Mid-2027 Topline Results | ||
SCHEDULE 13G | HBM Healthcare Investments (Cayman) Ltd. (Filed by) | ||
6-K | Vicore Pharma Announces Increase in Shares and Votes Following Incentive Program Exercise | ||
S-8 | Form S-8 | ||
6-K | Vicore Pharma Holding AB Q2 2026 Interim Report and U.S. Market Listing | ||
6-K | Vicore Pharma Appoints Rob Slack as Chief Scientific Officer | ||
ORDER | Form ORDER | ||
CERT | Form CERT | ||
20FR12B/A | Form 20FR12B/A | ||
20FR12B | Form 20FR12B |
